These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 27138571)
1. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Cives M; Soares HP; Strosberg J Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571 [TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
3. An update on gastroenteropancreatic neuroendocrine tumors. Cives M; Strosberg J Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471 [TBL] [Abstract][Full Text] [Related]
11. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087 [TBL] [Abstract][Full Text] [Related]
12. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Cives M; Strosberg J Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185 [TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Strosberg JR Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009 [TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of healthcare resource utilization and costs of [ Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254 [TBL] [Abstract][Full Text] [Related]
15. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Cloyd JM; Konda B; Shah MH; Pawlik TM Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383 [TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119 [TBL] [Abstract][Full Text] [Related]
18. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978 [TBL] [Abstract][Full Text] [Related]
19. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Saif MW Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177 [TBL] [Abstract][Full Text] [Related]
20. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]